1Sinnaeve PR, Simes J, Yusuf S, et al. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention[J]. Eur heart, 2005,26(22):2396-2403.
2Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin [J]. Am J Cardiol. 1998, 82(8B) : 12- 18.
3Yavin YY, Wolozinsky M, Cohen AT. New antithrombotics in the prevention of thromboembolic disease[J]. Eur J Intern Med,2005, 16(4) : 257 - 266.
4West N. Bivalirudin: role in current percutaneous coronary intervention praetice [ J ]. Br J Hosp Med ( Lond ), 2005,66 (12) : 687 - 689.
5Robson R. The use of bivalirudin in patients with renal impairment [J]. Invasive Cardiol, 2000, 12 (Suppl F) :33F- 6.
6Nawarskas J J, Anderson JR. Bivalirudin: a new approach to anti- coagulation [J]. Heart Dis, 2001,3:131-137.
8Sharma GV, lapsley D, Vita JA et ah Usefulness and tolerability of hiruloy, a direct Chrombin inhibitor, in unstable angina pectoris. [J]Am J Cardiol, 1993,72(18): 1357 -1360.
9Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glyeoprotein IIB/IIIa blockade compared with heparin and planned glycoprotein IIB/ IIIa blockade during percutaneous coronary intervention: replace-2, randomized, trial [J]. JAMA, 2003, 289(7):853 863.
10Bittl JA, Chaitman BR, Felt F, et al. Bivalirudin versu heparin during coronay angioplasty for unstable or postinfarction angina: Final report analysis of the Bivalirudin Angioplasty Study [ J ]. Am Heart J 2001, 142(6): 952- 959.
二级参考文献4
1Maraganore JM,Bourdon P,Jablonski J,et al.Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin[].Biochemistry.1990
2Robson R.The use of bivalirudin in patients with renal impairment[].Journal of Invasive Cardiology.2000
4BittlJA,StronyJ,BrinkerJA ,etal.Treatmentwithbivalirudin (Hirulog)ascomparedwithheparinduringcoronaryantioplastyforunstableorpostinfarctionangina.HirulogAngioplastyStudyInves tigators[].The New England Journal of Medicine.1995
6Doll JA, Nikolsky E, Stone GW, et al. Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombitic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials[J]. J Interv Cardiol, 2009, 22(5): 453-459.
7Bates SM. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin[J]. Am J Cardiol, 1998, 82(8): 12-18.
8Kleiman NS, Klem J, Femandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glyeoprotein II b/III a antagonist eptifibatide[J]. Am Heart J, 2002, 143(4): 585-593.
9White HD. Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome[J]. Expert Opin Drug Metab Toxicol, 2009, 5(5): 529-538.
